150-Page Report Forecasts Market Growth from $8.50B (2025) to $18.50B by 2034, Profiling Roche, Abbott, Siemens Healthineers, Thermo Fisher, Labcorp, and 5 Other Key Players

Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Blood Based Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

Blood Based Biomarkers Market Projected to Reach USD 18.50 Billion by 2034

The global blood based biomarkers market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 18.50 billion by 2034, expanding at a compound annual growth rate of 9.0% from 2026 to 2034. Market growth is being driven by the rising prevalence of cancer, cardiovascular conditions, neurological disorders, and other chronic diseases, alongside increasing demand for non-invasive diagnostics and precision medicine.

Blood based biomarker testing is becoming increasingly important across early disease detection, diagnosis, treatment selection, therapy monitoring, recurrence surveillance, companion diagnostics, and clinical research. Continued advances in liquid biopsy, next-generation sequencing, polymerase chain reaction, immunoassays, mass spectrometry, proteomics, and artificial intelligence are improving analytical performance and expanding clinical applications.

Key Blood Based Biomarkers Market Findings

The blood based biomarkers market was valued at an estimated USD 8.50 billion in 2025 and is forecast to reach USD 18.50 billion by 2034.
The market is projected to grow at a CAGR of 9.0% between 2026 and 2034.
Genetic biomarkers led the market by type, accounting for approximately 41% of revenue in 2025.
Oncology was the largest application segment, representing approximately 39% of the market in 2025.
Immunoassays dominated the technology category with an estimated 36% share in 2025.
Hospital and diagnostic laboratories held the largest end-user share at approximately 48% in 2025.
North America generated approximately 44% of global market revenue in 2025.
Asia-Pacific is expected to be the fastest-growing regional market through 2034.

Cancer Diagnostics and Liquid Biopsy Support Market Expansion

The increasing global cancer burden remains one of the most significant growth drivers for the blood based biomarkers market. The International Agency for Research on Cancer reported approximately 20 million new cancer cases in 2022 and projects the total to reach 35 million by 2050. This trend is increasing demand for blood-based oncology testing across screening, molecular profiling, targeted therapy selection, minimal residual disease assessment, and recurrence monitoring.

Liquid biopsy adoption is accelerating as circulating tumor DNA and cell-free DNA testing becomes more integrated into oncology workflows. Advances in sequencing and digital polymerase chain reaction are improving the detection of actionable mutations and treatment-resistance markers. These capabilities are strengthening the clinical and commercial position of genetic biomarkers, which represented the market's largest type segment in 2025.

Alzheimer's Blood Tests Create New Growth Opportunities

Neurological diseases are expected to represent one of the fastest-growing applications for blood based biomarkers. Aging populations and the increasing prevalence of Alzheimer's disease, Parkinson's disease, and related disorders are creating demand for scalable diagnostic tools. Phosphorylated tau biomarkers, including pTau217 and pTau181, have generated significant clinical interest for identifying pathology associated with Alzheimer's disease.

Regulatory progress is also accelerating adoption. In May 2025, Fujirebio Holdings received U.S. Food and Drug Administration 510(k) clearance for the Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test. The clearance marked an important step in the clinical adoption of blood-based testing designed to support the identification of amyloid pathology associated with Alzheimer's disease. In August 2025, Labcorp launched the cleared test nationwide, expanding access across the United States.

Market Segment Outlook

Genetic biomarkers accounted for approximately 41% of the blood based biomarkers market in 2025, supported by the expanding use of circulating tumor DNA, cell-free DNA, microRNA, and other nucleic-acid markers. Protein biomarkers also represent a substantial category, supported by established cardiac, oncology, and neurological assays. Cellular and metabolite biomarkers are expected to benefit from ongoing advances in precision medicine and multi-analyte testing.

Oncology led the application market with an estimated 39% share in 2025. Cardiovascular testing remains a major application due to high testing volumes and the established use of cardiac biomarkers. Neurological testing is forecast to expand rapidly as Alzheimer's blood tests enter clinical practice, while metabolic and other disease applications continue to generate recurring demand.

Hospital and diagnostic laboratories represented approximately 48% of market revenue in 2025. Their leadership reflects high test volumes, established laboratory infrastructure, broad assay availability, and direct integration with patient-care pathways. Reference laboratories are also expanding their role by offering specialized liquid biopsy, molecular, and ultra-sensitive neurological testing.

Regional Blood Based Biomarkers Market Analysis

North America dominated the global blood based biomarkers market with approximately 44% of revenue in 2025. Regional leadership is supported by advanced healthcare infrastructure, substantial diagnostic spending, extensive research funding, strong clinical adoption, and the presence of major diagnostics and liquid biopsy companies. The United States also leads in regulatory activity and commercialization of emerging Alzheimer's and oncology blood tests.

Asia-Pacific is projected to record the fastest growth through 2034. Expansion is being supported by aging populations, increasing cancer and chronic disease prevalence, improving laboratory infrastructure, greater healthcare investment, and growing adoption of advanced diagnostics in China, Japan, India, South Korea, and Australia. Europe remains a major market, backed by established public health systems, active biomarker research, and a strong diagnostics industry.

Competitive Landscape

The blood based biomarkers market is moderately concentrated, combining multinational diagnostics companies with specialized molecular testing, liquid biopsy, and neurological biomarker developers. Competition is shaped by clinical evidence, regulatory clearances, assay sensitivity, platform scalability, geographic reach, strategic partnerships, and integration with pharmaceutical development programs.

Major companies active in the market include:

F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
Bio-Rad Laboratories, Inc.
Quanterix Corporation
Fujirebio Holdings, Inc.
Guardant Health, Inc.

Market Challenges and Future Outlook

Despite strong growth prospects, the market faces challenges associated with analytical validation, clinical evidence requirements, reimbursement variability, evolving regulatory pathways, and limited assay standardization. High platform costs and the need for specialized laboratory expertise may also restrict adoption in lower-resource settings. In some applications, confirmatory imaging, tissue analysis, or additional testing remains necessary.

Nevertheless, the long-term outlook for the blood based biomarkers market remains positive. Rising disease prevalence, broader liquid biopsy adoption, regulatory momentum, expanding laboratory access, and innovation in multi-biomarker panels are expected to support sustained growth. The integration of artificial intelligence, proteomics, genomics, and advanced molecular diagnostics is also likely to strengthen the role of blood based biomarkers in preventive care, precision medicine, drug development, and long-term disease management through 2034.

Key Topics Covered:

1. Blood Based Biomarkers Market Report Introduction
1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. Blood Based Biomarkers Market Executive Summary
2.1 Market at a Glance

3. Blood Based Biomarkers Market Key Factors Analysis
3.1 Blood Based Biomarkers Market Drivers
3.1.1 Rising Cancer Burden and Liquid Biopsy
3.1.2 Neurological Disease and Alzheimer's Blood Tests
3.1.3 Regulatory Clearances and Guideline Support
3.1.4 Non-Invasive Testing and Molecular Advances
3.2 Blood Based Biomarkers Market Restraints and Challenges
3.2.1 Validation, Sensitivity, and Confirmatory Testing
3.2.2 Reimbursement and Regulatory Pathways
3.2.3 Standardization and Infrastructure Barriers
3.3 Blood Based Biomarkers Market Opportunities
3.3.1 Neurology, Multi-Omics, and AI Panels
3.3.2 Companion Diagnostics and Emerging Markets

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis
5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. Blood Based Biomarkers Market Porter's Five Forces Analysis
6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. Blood Based Biomarkers Market Assessment
7.1 By Type
7.1.1 Genetic Biomarkers
7.1.2 Protein Biomarkers
7.1.3 Cellular Biomarkers
7.1.4 Metabolite Biomarkers
7.2 By Application
7.2.1 Oncology
7.2.2 Cardiovascular Diseases
7.2.3 Neurological Diseases
7.2.4 Metabolic and Other Diseases
7.3 By Technology
7.3.1 Immunoassays
7.3.2 Polymerase Chain Reaction
7.3.3 Next-Generation Sequencing
7.3.4 Mass Spectrometry
7.3.5 Others
7.4 By Sample Type
7.4.1 Whole Blood
7.4.2 Plasma
7.4.3 Serum
7.5 By End User
7.5.1 Hospital and Diagnostic Laboratories
7.5.2 Reference Laboratories
7.5.3 Academic and Research Institutes
7.5.4 Pharmaceutical and Biotechnology Companies
7.6 By Geography
7.6.1 North America
7.6.1.1 United States Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.1.2 Canada Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.1.3 Mexico Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.2 Europe
7.6.2.1 Germany Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.2.2 United Kingdom Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.2.3 France Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.2.4 Italy Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.2.5 Spain Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.2.6 Rest of Europe Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.3 Asia-Pacific
7.6.3.1 China Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.3.2 Japan Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.3.3 India Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.3.4 South Korea Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.3.5 Australia Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.3.6 Rest of Asia-Pacific Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.4 Rest of World
7.6.4.1 Middle East Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.4.2 Africa Blood Based Biomarkers Market Size in USD million (2023-2034)
7.6.4.3 South America Blood Based Biomarkers Market Size in USD million (2023-2034)

8. Blood Based Biomarkers Market Competitive Landscape
8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Blood Based Biomarkers Market Startup Funding and Investment Trends

10. Blood Based Biomarkers Market Company and Product Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Financial Overview
10.1.4 Product Portfolio
10.1.5 Strategic Initiatives / Entropy
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Company Snapshot
10.2.3 Financial Overview
10.2.4 Product Portfolio
10.2.5 Strategic Initiatives / Entropy
10.3 Siemens Healthineers AG
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Financial Overview
10.3.4 Product Portfolio
10.3.5 Strategic Initiatives / Entropy
10.4 Thermo Fisher Scientific Inc.
10.4.1 Company Overview
10.4.2 Company Snapshot
10.4.3 Financial Overview
10.4.4 Product Portfolio
10.4.5 Strategic Initiatives / Entropy
10.5 Quest Diagnostics Incorporated
10.5.1 Company Overview
10.5.2 Company Snapshot
10.5.3 Financial Overview
10.5.4 Product Portfolio
10.5.5 Strategic Initiatives / Entropy
10.6 Laboratory Corporation of America Holdings
10.6.1 Company Overview
10.6.2 Company Snapshot
10.6.3 Financial Overview
10.6.4 Product Portfolio
10.6.5 Strategic Initiatives / Entropy
10.7 Bio-Rad Laboratories, Inc.
10.7.1 Company Overview
10.7.2 Company Snapshot
10.7.3 Financial Overview
10.7.4 Product Portfolio
10.7.5 Strategic Initiatives / Entropy
10.8 Quanterix Corporation
10.8.1 Company Overview
10.8.2 Company Snapshot
10.8.3 Financial Overview
10.8.4 Product Portfolio
10.8.5 Strategic Initiatives / Entropy
10.9 Fujirebio Holdings, Inc.
10.9.1 Company Overview
10.9.2 Company Snapshot
10.9.3 Financial Overview
10.9.4 Product Portfolio
10.9.5 Strategic Initiatives / Entropy
10.10 Guardant Health, Inc.
10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About the Publisher

14. Disclaimer and Contact Us

List of Tables
Table 1: Blood Based Biomarkers Market in Global (2023-2034)
Table 2: Blood Based Biomarkers Market in Global by Type (2023-2034)
Table 3: Blood Based Biomarkers Market in Global by Application (2023-2034)
Table 4: Blood Based Biomarkers Market in Global by Technology (2023-2034)
Table 5: Blood Based Biomarkers Market in Global by Sample Type (2023-2034)
Table 6: Blood Based Biomarkers Market in Global by End User (2023-2034)
Table 7: Blood Based Biomarkers Market in Global by Geography (2023-2034)
Table 8: Blood Based Biomarkers Market in North America (2023-2034)
Table 9: Blood Based Biomarkers Market in the United States (2023-2034)
Table 10: Blood Based Biomarkers Market in Canada (2023-2034)
Table 11: Blood Based Biomarkers Market in Mexico (2023-2034)
Table 12: Blood Based Biomarkers Market in Europe (2023-2034)
Table 13: Blood Based Biomarkers Market in Germany (2023-2034)
Table 14: Blood Based Biomarkers Market in United Kingdom (2023-2034)
Table 15: Blood Based Biomarkers Market in France (2023-2034)
Table 16: Blood Based Biomarkers Market in Italy (2023-2034)
Table 17: Blood Based Biomarkers Market in Spain (2023-2034)
Table 18: Blood Based Biomarkers Market in the Rest of Europe (2023-2034)
Table 19: Blood Based Biomarkers Market in Asia-Pacific (2023-2034)
Table 20: Blood Based Biomarkers Market in China (2023-2034)
Table 21: Blood Based Biomarkers Market in Japan (2023-2034)
Table 22: Blood Based Biomarkers Market in India (2023-2034)
Table 23: Blood Based Biomarkers Market in South Korea (2023-2034)
Table 24: Blood Based Biomarkers Market in Australia (2023-2034)
Table 25: Blood Based Biomarkers Market in Rest of Asia-Pacific (2023-2034)
Table 26: Blood Based Biomarkers Market in the Rest of the World (2023-2034)
Table 27: Blood Based Biomarkers Market in the Middle East (2023-2034)
Table 28: Blood Based Biomarkers Market in Africa (2023-2034)
Table 29: Blood Based Biomarkers Market in South America (2023-2034)
Table 30: Competitive Landscape
Table 31: Startup Funding and Investment Trends

List of Figures
Figure 1: Blood Based Biomarkers Market Drivers
Figure 2: Blood Based Biomarkers Market Restraints
Figure 3: Blood Based Biomarkers Market Opportunities
Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
Figure 5: Regulatory Analysis (US, EU, Japan, China)
Figure 6: Porter's Five Forces Analysis
Figure 7: Competitive Analysis
Figure 8: Blood Based Biomarkers Market in Global (2023-2034)
Figure 9: Blood Based Biomarkers Market in Global by Type (2023-2034)
Figure 10: Blood Based Biomarkers Market in Global by Application (2023-2034)
Figure 11: Blood Based Biomarkers Market in Global by Technology (2023-2034)
Figure 12: Blood Based Biomarkers Market in Global by Sample Type (2023-2034)
Figure 13: Blood Based Biomarkers Market in Global by End User (2023-2034)
Figure 14: Blood Based Biomarkers Market in Global by Geography (2023-2034)
Figure 15: Blood Based Biomarkers Market in North America (2023-2034)
Figure 16: Blood Based Biomarkers Market in the United States (2023-2034)
Figure 17: Blood Based Biomarkers Market in Canada (2023-2034)
Figure 18: Blood Based Biomarkers Market in Mexico (2023-2034)
Figure 19: Blood Based Biomarkers Market in Europe (2023-2034)
Figure 20: Blood Based Biomarkers Market in Germany (2023-2034)
Figure 21: Blood Based Biomarkers Market in United Kingdom (2023-2034)
Figure 22: Blood Based Biomarkers Market in France (2023-2034)
Figure 23: Blood Based Biomarkers Market in Italy (2023-2034)
Figure 24: Blood Based Biomarkers Market in Spain (2023-2034)
Figure 25: Blood Based Biomarkers Market in the Rest of Europe (2023-2034)
Figure 26: Blood Based Biomarkers Market in Asia-Pacific (2023-2034)
Figure 27: Blood Based Biomarkers Market in China (2023-2034)
Figure 28: Blood Based Biomarkers Market in Japan (2023-2034)
Figure 29: Blood Based Biomarkers Market in India (2023-2034)
Figure 30: Blood Based Biomarkers Market in South Korea (2023-2034)
Figure 31: Blood Based Biomarkers Market in Australia (2023-2034)
Figure 32: Blood Based Biomarkers Market in Rest of Asia-Pacific (2023-2034)
Figure 33: Blood Based Biomarkers Market in the Rest of the World (2023-2034)
Figure 34: Blood Based Biomarkers Market in the Middle East (2023-2034)
Figure 35: Blood Based Biomarkers Market in Africa (2023-2034)
Figure 36: Blood Based Biomarkers Market in South America (2023-2034)
Figure 37: Competitive Landscape
Figure 38: Startup Funding and Investment Trends

A selection of companies mentioned in this report includes, but is not limited to:

F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
Bio-Rad Laboratories, Inc.
Quanterix Corporation
Fujirebio Holdings, Inc.
Guardant Health, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/34vpzf

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

Blood Based Biomarkers Market Report Now Available — See Why the First FDA-Cleared Alzheimer's Blood Test Just Redrew the Competitive Map